Načítá se...
Alogliptin benzoate for management of type 2 diabetes
Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress glucagon levels through enhancement of the action of endogenous incretin by inhibiting DPP-4, an incretin-degrading enzyme. DPP-4 inhibitors are generally well...
Uloženo v:
| Vydáno v: | Vasc Health Risk Manag |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4401208/ https://ncbi.nlm.nih.gov/pubmed/25914541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S68564 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|